PAPER Mehrabian S, Duron E, Labouree F, Rollot F, Bune A, Traykov L, Hanon O
SEARCH RESULTS
329930 RESULTS
PAPER Ankolekar S, Geeganage C, Anderton P, Hogg C, Bath PM
Clinical trials for preventing post stroke cognitive impairment.
J Neurol Sci. 2010 Dec 15;299(1-2):168-74. PubMed: 20855090PAPER Schuff N, Tosun D, Insel PS, Chiang GC, Truran D, Aisen PS, Jack CR, Weiner MW,
Nonlinear time course of brain volume loss in cognitively normal and impaired elders.
Neurobiol Aging. 2010 Sep 18; PubMed: 20855131PAPER Hou DR, Xue L, Tang JC, Zhou J, Sun JJ
[Butylphthalide improves learning and memory abilities of rats with Alzheimer's disease possibly by enhancing protein disulfide isomerase and inhibiting P53 expressions].
Nan Fang Yi Ke Da Xue Xue Bao. 2010 Sep;30(9):2104-7. PubMed: 20855262PAPER Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE, Südhof TC, Zheng H
Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP.
Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17362-7. PubMed: 20855613PAPER Peavy GM
Mild cognitive deficits in Parkinson disease: where there is bradykinesia, there is bradyphrenia.
Neurology. 2010 Sep 21;75(12):1038-9. PubMed: 20855847PAPER Jefferson AL, Lambe S, Cook E, Pimontel M, Palmisano J, Chaisson C
Factors associated with African American and White elders' participation in a brain donation program.
Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):11-6. PubMed: 20856099PAPER Kramberger MG, Stukovnik V, Cus A, Repovs G, Tomse P, Meglic NP, Garasević Z, Jensterle J, Pirtosek Z
Parkinson's disease dementia: clinical correlates of brain spect perfusion and treatment.
Psychiatr Danub. 2010 Sep;22(3):446-9. PubMed: 20856190PAPER Ohtsuki S, Ito S, Terasaki T
Is P-glycoprotein involved in amyloid-β elimination across the blood-brain barrier in Alzheimer's disease?
Clin Pharmacol Ther. 2010 Oct;88(4):443-5. PubMed: 20856239PAPER Jedlitschky G, Vogelgesang S, Kroemer HK
MDR1-P-glycoprotein (ABCB1)-mediated disposition of amyloid-β peptides: implications for the pathogenesis and therapy of Alzheimer's disease.
Clin Pharmacol Ther. 2010 Oct;88(4):441-3. PubMed: 20856238PAPER Rockwood K
An individualized approach to tracking and treating Alzheimer's disease.
Clin Pharmacol Ther. 2010 Oct;88(4):446-9. PubMed: 20856240PAPER Roberts JS, Tersegno SM
Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions.
Future Neurol. 2010 Jul 1;5(4):501-517. PubMed: 20856693PAPER Xia W
Brain amyloid β protein and memory disruption in Alzheimer's disease.
Neuropsychiatr Dis Treat. 2010;6:605-11. PubMed: 20856923PAPER Lebedeva E, Stingl JC, Thal DR, Ghebremedhin E, Strauss J, Özer E, Bertram L, von Einem B, Tumani H, Otto M, Riepe MW, Högel J, Ludolph AC, von Arnim CA
Genetic variants in PSEN2 and correlation to CSF β-amyloid42 levels in AD.
Neurobiol Aging. 2012 Jan;33(1):201.e9-18. PubMed: 20850903PAPER Zhang D, Zhang C, Ho A, Kirkwood A, Südhof TC, Shen J
Inactivation of presenilins causes pre-synaptic impairment prior to post-synaptic dysfunction.
J Neurochem. 2010 Dec;115(5):1215-21. Epub 2010 Oct 26 PubMed: 20854432Current Filters
No filters selected